全文获取类型
收费全文 | 1593564篇 |
免费 | 133688篇 |
国内免费 | 2562篇 |
专业分类
耳鼻咽喉 | 21681篇 |
儿科学 | 52860篇 |
妇产科学 | 46280篇 |
基础医学 | 226318篇 |
口腔科学 | 47250篇 |
临床医学 | 140464篇 |
内科学 | 312617篇 |
皮肤病学 | 34089篇 |
神经病学 | 129519篇 |
特种医学 | 64728篇 |
外国民族医学 | 474篇 |
外科学 | 243571篇 |
综合类 | 39734篇 |
现状与发展 | 3篇 |
一般理论 | 545篇 |
预防医学 | 122424篇 |
眼科学 | 36384篇 |
药学 | 121125篇 |
2篇 | |
中国医学 | 2879篇 |
肿瘤学 | 86867篇 |
出版年
2018年 | 14816篇 |
2016年 | 12939篇 |
2015年 | 15090篇 |
2014年 | 20715篇 |
2013年 | 31470篇 |
2012年 | 42732篇 |
2011年 | 44927篇 |
2010年 | 26411篇 |
2009年 | 25364篇 |
2008年 | 43144篇 |
2007年 | 45375篇 |
2006年 | 46191篇 |
2005年 | 44837篇 |
2004年 | 44200篇 |
2003年 | 42181篇 |
2002年 | 41336篇 |
2001年 | 75672篇 |
2000年 | 78222篇 |
1999年 | 66055篇 |
1998年 | 16736篇 |
1997年 | 15368篇 |
1996年 | 15304篇 |
1995年 | 15966篇 |
1994年 | 15009篇 |
1993年 | 14179篇 |
1992年 | 55430篇 |
1991年 | 53808篇 |
1990年 | 52594篇 |
1989年 | 50846篇 |
1988年 | 47232篇 |
1987年 | 46587篇 |
1986年 | 44302篇 |
1985年 | 42879篇 |
1984年 | 32039篇 |
1983年 | 27556篇 |
1982年 | 16105篇 |
1981年 | 14395篇 |
1980年 | 13519篇 |
1979年 | 30443篇 |
1978年 | 21059篇 |
1977年 | 17725篇 |
1976年 | 16671篇 |
1975年 | 17548篇 |
1974年 | 21474篇 |
1973年 | 20669篇 |
1972年 | 18875篇 |
1971年 | 17768篇 |
1970年 | 16296篇 |
1969年 | 15272篇 |
1968年 | 13950篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
S. Harrogate J. Barnes K. Thomas A. Isted G. Kunst S. Gupta S. Rudd T. Banerjee R. Hinchliffe R. Mouton 《Anaesthesia》2023,78(11):1393-1408
Tobacco smoking is associated with a substantially increased risk of postoperative complications. The peri-operative period offers a unique opportunity to support patients to stop tobacco smoking, avoid complications and improve long-term health. This systematic review provides an up-to-date summary of the evidence for tobacco cessation interventions in surgical patients. We conducted a systematic search of randomised controlled trials of tobacco cessation interventions in the peri-operative period. Quantitative synthesis of the abstinence outcomes data was by random-effects meta-analysis. The primary outcome of the meta-analysis was abstinence at the time of surgery, and the secondary outcome was abstinence at 12 months. Thirty-eight studies are included in the review (7310 randomised participants) and 26 studies are included in the meta-analysis (5969 randomised participants). Studies were pooled for subgroup analysis in two ways: by the timing of intervention delivery within the peri-operative period and by the intensity of the intervention protocol. We judged the quality of evidence as moderate, reflecting the degree of heterogeneity and the high risk of bias. Overall, peri-operative tobacco cessation interventions increased successful abstinence both at the time of surgery, risk ratio (95%CI) 1.48 (1.20–1.83), number needed to treat 7; and 12 months after surgery, risk ratio (95%CI) 1.62 (1.29–2.03), number needed to treat 9. More work is needed to inform the design and optimal delivery of interventions that are acceptable to patients and that can be incorporated into contemporary elective and urgent surgical pathways. Future trials should use standardised outcome measures. 相似文献
14.
15.
16.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
17.
18.
Münch F. Purbojo A. Wenzel F. Kohl M. Dittrich S. Rauh M. Zimmermann R. Kwapil N. 《Der Anaesthesist》2022,71(11):882-892
Die Anaesthesiologie - Die Transfusion von Erythrozytenkonzentraten (EK) ist mit verschiedenen Nebenwirkungen assoziiert, die u. a. durch Lagerungsschäden an Erythrozyten hervorgerufen... 相似文献
19.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
20.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097